Compare Stocks: SANA, CDNA, AMLX, and ELVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$27.79 -1.0%	$29.64	$10.83 ▼ $41.14	$3.10B	-0.1	1.37 million shs	912,369 shs
CDNA CareDx	$67.15 +1.4%	$50.53	$13.95 ▼ $69.80	$3.47B	2.38	1.28 million shs	1.59 million shs
ELVN Enliven Therapeutics	$46.97 +1.6%	$55.23	$14.78 ▼ $62.32	$3.44B	0.24	1.46 million shs	1.12 million shs
SANA Sana Biotechnology	$2.89	$3.44	$2.61 ▼ $6.55	$865.15M	2.18	3.97 million shs	3.50 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	-5.76%	-18.17%	+52.11%	+98.50%
CDNA CareDx	0.00%	+5.45%	+34.68%	+130.04%	+347.67%
ELVN Enliven Therapeutics	0.00%	+4.96%	-21.26%	-5.72%	+136.86%
SANA Sana Biotechnology	0.00%	-1.70%	-26.28%	-27.93%	-21.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$27.79 -1.0%	$29.64	$10.83 ▼ $41.14	$3.10B	-0.1	1.37 million shs	912,369 shs
CDNA CareDx	$67.15 +1.4%	$50.53	$13.95 ▼ $69.80	$3.47B	2.38	1.28 million shs	1.59 million shs
ELVN Enliven Therapeutics	$46.97 +1.6%	$55.23	$14.78 ▼ $62.32	$3.44B	0.24	1.46 million shs	1.12 million shs
SANA Sana Biotechnology	$2.89	$3.44	$2.61 ▼ $6.55	$865.15M	2.18	3.97 million shs	3.50 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	-5.76%	-18.17%	+52.11%	+98.50%
CDNA CareDx	0.00%	+5.45%	+34.68%	+130.04%	+347.67%
ELVN Enliven Therapeutics	0.00%	+4.96%	-21.26%	-5.72%	+136.86%
SANA Sana Biotechnology	0.00%	-1.70%	-26.28%	-27.93%	-21.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$38.86	39.82% Upside
CDNA CareDx	2.63	Moderate Buy	$54.00	-19.58% Downside
ELVN Enliven Therapeutics	2.82	Moderate Buy	$74.44	58.49% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	222.95% Upside

Current Analyst Ratings Breakdown

Latest SANA, CDNA, AMLX, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	ELVN Enliven Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
10/1/2026	ELVN Enliven Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$75.00
9/24/2026	CDNA CareDx	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $74.00
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
8/27/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $57.00
8/24/2026	SANA Sana Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/19/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $55.00
8/19/2026	AMLX Amylyx Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$28.00 ➝ $52.00
8/18/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $42.00
8/18/2026	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $55.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	35.44	N/A	N/A	$2.78 per share	10.00
CDNA CareDx	$379.80M	9.15	$0.01 per share	10,309.52	$5.89 per share	11.40
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$7.74 per share	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
CDNA CareDx	-$21.35M	$2.07	32.44	106.59	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
ELVN Enliven Therapeutics	-$103.69M	-$1.67	N/A	N/A	N/A	N/A	-18.55%	-18.09%	11/11/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)

Latest SANA, CDNA, AMLX, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/5/2026	Q2 2026	ELVN Enliven Therapeutics	-$0.3872	-$0.49	-$0.1028	-$0.49	N/A	N/A
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
CDNA CareDx	N/A	4.58	4.51
ELVN Enliven Therapeutics	N/A	64.07	64.07
SANA Sana Biotechnology	N/A	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
CDNA CareDx	N/A
ELVN Enliven Therapeutics	95.08%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
CDNA CareDx	2.40%
ELVN Enliven Therapeutics	3.00%
SANA Sana Biotechnology	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	136	111.42 million	99.28 million	Optionable
CDNA CareDx	765	51.73 million	50.49 million	Optionable
ELVN Enliven Therapeutics	67	73.27 million	71.07 million	Optionable
SANA Sana Biotechnology	142	299.36 million	223.32 million	Optionable

SANA, CDNA, AMLX, and ELVN Headlines

Recent News About These Companies

Bank of America Corp DE Purchases New Holdings in Sana Biotechnology, Inc. $SANA

September 25, 2026 | marketbeat.com

6 'moonshot' biotech stocks that offer big risks, bigger rewards

September 23, 2026 | msn.com

Sana Biotechnology (NASDAQ:SANA) Shares Down 7.2% - Should You Sell?

September 23, 2026 | marketbeat.com

Sana Biotechnology (SANA)

September 23, 2026 | es.investing.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 10.4% - Still a Buy?

September 17, 2026 | marketbeat.com

Sana Biotechnology, Inc. (SANA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

September 15, 2026 | seekingalpha.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Brokerages

September 15, 2026 | marketbeat.com

Sana Biotechnology op Morgan Stanley conferentie: focus op diabetes

September 15, 2026 | nl.investing.com

Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Sana Biotechnology出席富国银行医疗健康大会：两大核心项目即将进入临床阶段

September 10, 2026 | cn.investing.com

Sana Biotechnology出席花旗2026年生物医药返校峰会：押注糖尿病疗法

September 10, 2026 | cn.investing.com

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 10, 2026 | seekingalpha.com

Bank of New York Mellon Corp Invests $1.67 Million in Sana Biotechnology, Inc. $SANA

September 9, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 7.9% - What's Next?

September 8, 2026 | marketbeat.com

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

September 7, 2026 | prnewswire.com

Sana Biotechnology to Present at September 2026 Investor Conferences

September 1, 2026 | globenewswire.com

As U.S.-China biotech race heats up, Seattle makes its case to D.C.

August 27, 2026 | msn.com

As US.-China biotech race heats up, Seattle makes its case to DC

August 27, 2026 | msn.com

Sana Biotechnology (NASDAQ:SANA) Cell Therapy Vision Gains Attention

August 21, 2026 | kalkinemedia.comK

Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA)

August 19, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, CDNA, AMLX, and ELVN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$27.79 -0.29 (-1.03%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$27.80 +0.02 (+0.05%)

As of 10/2/2026 07:30 PM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

CareDx NASDAQ:CDNA

$67.15 +0.92 (+1.39%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$68.66 +1.51 (+2.24%)

As of 10/2/2026 07:58 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Enliven Therapeutics NASDAQ:ELVN

$46.97 +0.76 (+1.64%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$46.70 -0.27 (-0.56%)

As of 10/2/2026 07:30 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Sana Biotechnology NASDAQ:SANA

$2.89 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.88 -0.01 (-0.35%)

As of 10/2/2026 07:30 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SANA, CDNA, AMLX, and ELVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SANA, CDNA, AMLX, and ELVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SANA, CDNA, AMLX, and ELVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, CDNA, AMLX, and ELVN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

CareDx NASDAQ:CDNA

Enliven Therapeutics NASDAQ:ELVN

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SANA, CDNA, AMLX, and ELVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SANA, CDNA, AMLX, and ELVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SANA, CDNA, AMLX, and ELVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, CDNA, AMLX, and ELVN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

CareDx NASDAQ:CDNA

Enliven Therapeutics NASDAQ:ELVN

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools